John Allan, MD, Weill Cornell Medicine, New York, New York, discusses results from analysis exploring the long-term efficacy of first-line ibrutinib in patients with chronic lymphocytic leukemia (CLL) and TP53 mutations.
These results were presented at the virtual American Society of Hematology (ASH) 62nd Annual Meeting.